HC Wainwright Issues Positive Outlook for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Stock analysts at HC Wainwright upped their Q1 2025 EPS estimates for shares of Allogene Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

A number of other analysts have also commented on the company. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Friday, March 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.29.

Allogene Therapeutics Stock Performance

NASDAQ ALLO opened at $1.63 on Friday. The stock has a market capitalization of $354.14 million, a P/E ratio of -1.04 and a beta of 1.02. Allogene Therapeutics has a 52 week low of $1.32 and a 52 week high of $4.63. The stock has a fifty day moving average of $1.89 and a 200-day moving average of $2.29.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06.

Insiders Place Their Bets

In other news, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO David D. Chang sold 46,668 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the transaction, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This represents a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,866 shares of company stock worth $194,461. Company insiders own 24.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Cibc World Markets Corp acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth $26,000. PAX Financial Group LLC acquired a new stake in Allogene Therapeutics in the 4th quarter valued at $27,000. RPO LLC acquired a new stake in Allogene Therapeutics in the 4th quarter valued at $31,000. Caption Management LLC bought a new stake in Allogene Therapeutics during the 4th quarter worth about $32,000. Finally, Syon Capital LLC acquired a new position in shares of Allogene Therapeutics during the 4th quarter worth about $39,000. Institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).